Source: China – South China Morning PostStemirna Therapeutics is preparing to launch a global multi-site human trials of its Covid-19 vaccine soon as the firm pushes for the second Chinese-made shot based on mRNA technology to protect against the coronavirus.Li Hangwen, co-founder and chief executive of the Shanghai-based start-up, said the firm is capable of producing 400 million doses a year from its facilities in mainland China, broadening the options for China’s vaccination campaign once it receives an approval from local…Read More